- Home
- GCTS vs KZIA Comparison
GCTS vs KZIA Comparison
Compare GCTS & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GCTS | KZIA |
|---|---|---|
| Founded | 1998 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.1M | 74.4M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | GCTS | KZIA |
|---|---|---|
| Price | $1.14 | $6.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $3.50 | ★ $17.67 |
| AVG Volume (30 Days) | ★ 256.5K | 247.9K |
| Earning Date | 11-12-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,893,000.00 | $1,199,108.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,184.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.90 | $2.86 |
| 52 Week High | $2.65 | $17.40 |
Technical Indicators
Market Signals| Indicator | GCTS | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 36.43 | 41.69 |
| Support Level | $1.08 | $5.30 |
| Resistance Level | $1.27 | $7.11 |
| Average True Range (ATR) | 0.09 | 1.18 |
| MACD | -0.01 | -0.20 |
| Stochastic Oscillator | 17.64 | 22.96 |
Price Performance
Historical ComparisonAbout GCTS GCT Semiconductor Holding Inc.
GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.